{"id":"cisplatin-capecitabine-telatinib","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-80%","effect":"Neutropenia"},{"rate":"10-50%","effect":"Thrombocytopenia"},{"rate":"10-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cisplatin's mechanism of action involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription. Capecitabine's active metabolite, 5-fluorouracil, is a thymidylate synthase inhibitor, which prevents DNA synthesis. Telatinib's inhibition of VEGFR and PDGFR pathways disrupts angiogenesis and cell proliferation.","oneSentence":"Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, and Telatinib is a tyrosine kinase inhibitor that targets the VEGFR and PDGFR pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:48.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer, Renal cell carcinoma"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT00952497","phase":"PHASE2","title":"A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"ACT Biotech, Inc","startDate":"2009-06","conditions":"Gastric Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cisplatin, Capecitabine, Telatinib","genericName":"Cisplatin, Capecitabine, Telatinib","companyName":"ACT Biotech, Inc","companyId":"act-biotech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, and Telatinib is a tyrosine kinase inhibitor that targets the VEGFR and PDGFR pathways. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer, Renal cell carcinoma, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}